Omeros Co. (NASDAQ:OMER) Shares Sold by Corient Private Wealth LLC

Corient Private Wealth LLC lessened its stake in shares of Omeros Co. (NASDAQ:OMER - Free Report) by 6.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 733,449 shares of the biopharmaceutical company's stock after selling 53,002 shares during the quarter. Corient Private Wealth LLC owned 1.27% of Omeros worth $7,246,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Truvestments Capital LLC raised its holdings in shares of Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 1,669 shares during the period. Picton Mahoney Asset Management lifted its position in shares of Omeros by 692.5% during the fourth quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company's stock worth $50,000 after purchasing an additional 4,404 shares in the last quarter. US Bancorp DE purchased a new position in shares of Omeros in the fourth quarter valued at approximately $81,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Omeros in the fourth quarter valued at approximately $121,000. Finally, BNP Paribas Financial Markets lifted its holdings in Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company's stock worth $49,000 after buying an additional 7,016 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Omeros Trading Up 1.6 %

Shares of NASDAQ OMER traded up $0.14 during mid-day trading on Tuesday, reaching $9.16. The company had a trading volume of 247,017 shares, compared to its average volume of 529,998. The firm has a 50 day simple moving average of $8.71 and a two-hundred day simple moving average of $7.40. The stock has a market cap of $530.82 million, a P/E ratio of -3.97 and a beta of 2.03. Omeros Co. has a 52-week low of $2.61 and a 52-week high of $13.60.

Remove Ads

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on OMER shares. Needham & Company LLC reiterated a "hold" rating on shares of Omeros in a report on Friday, January 17th. D. Boral Capital reiterated a "buy" rating and set a $36.00 price target on shares of Omeros in a report on Friday. Finally, StockNews.com downgraded shares of Omeros from a "hold" rating to a "sell" rating in a research report on Friday. One research analyst has rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $22.50.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.